Introduction
============

"Tumor-associated antigens" are multi-faceted and can be defined as any entity that the immune system can avail itself of to protect the host from disease. Virus-encoded tumor antigens are currently being targeted by preventive vaccines, such as for papilloma viruses, or by adoptive immunotherapy, as in EBV-associated post-transplant lymphoma. Self-antigens presented on major histocompatibility antigens (MHC) molecules are also key to clearing disease by donor-derived cells in the context of bone-marrow or hematopoietic stem cell transplantation (HSCT; Miller et al., [@B35]). However, with the advent of antibody-based therapies, cell-surface antigens on tumor cells can be targeted without first requiring processing and presentation by the MHC. Thus, a tumor antigen may be a unique molecule expressed by a tumor that is not encoded by the healthy genome, a non-mutated developmental antigen now re-expressed on a tumor cell, or a self-antigen than can be safely targeted without loss of host integrity. One example of recent interest is the re-expression of the developmentally regulated ALK protein on neuroblastoma (Mosse et al., [@B37]). The work we present here indicates that there are other such targets that remain to be discovered.

Our goal was to develop a method for identifying tumor antigen candidates that could be targeted by antibody or CAR-based therapies by leveraging publically available microarray gene expression databases of pediatric cancer. Previously we explored a series of established xenograft cell lines from pediatric cancers in support of the Pediatric Oncology Pre-clinical Protein-Tissue Array Project (POPP-TAP), a project jointly supported by the Children's Oncology Group and the NCI (Whiteford et al., [@B53]). In analyzing these xenograft models we also began to assemble comparator normal tissue databases[^1^](#fn1){ref-type="fn"} ("Pediatric Xenograft & Tumor Gene Expression Database"). This earlier study was carried out using a gene expression array from Research Genetics (Huntsville, AL, USA). These studies were expanded to include normal tissue analysis on the commonly available Affymetrix platform ("Pediatric Tumor Affymetrix Database" at see text footnote 1), allowing for easier comparison to analyses from other groups (Chen et al., [@B6]). Averaging gene expression levels from individual tumor samples according to diagnostic category, and comparing this expression level transcript by transcript to average normal tissue expression levels, allowed a statistical measure of the difference of that transcripts expression from its expression in normal tissue. Ranking the identified transcripts, and then filtering them for plasma membrane expression is a first step in the high-throughput identification of all available targets on the surface of pediatric cancers. We propose that this approach will be especially valuable in solid tumors, as a paucity of well-described targets remains a challenge to the field. The data we present here should allow for the rapid assessment of these target antigens for their suitability as candidates for immunotherapy.

Materials and Methods
=====================

Expression database for pediatric tumors
----------------------------------------

The Pediatric Tumor Affymetrix Database is freely accessible and can be found on-line at the NCI Pediatric Oncology Branch Oncogenomics Section web-site[^2^](#fn2){ref-type="fn"}. The gene chip used was U133 P2 (Affymetrix, Santa Clara, CA, USA).

Construction of an algorithm to identify candidate membrane proteins following disease-specific analysis of gene expression
---------------------------------------------------------------------------------------------------------------------------

The design of this program was broken down into stages. First, annotation data from several public databases were collated and used to identify cell surface proteins. This included Gene Ontology[^3^](#fn3){ref-type="fn"}, Affymetrix chip data references, the Human Protein Reference Database[^4^](#fn4){ref-type="fn"}, and the primary literature. Second, a database was constructed using this data, along with our gene expression data, to store the data in a usable format for analysis in MySQL, using a set of Python scripts to automate core database functions. Using this database, an auxiliary table was built, combining gene expression levels over tissue sample categories, corresponding specifically to samples from indicated pediatric cancers, using a two-sampled *t*-test (implemented using the SciPy Python package for scientific and statistical functions) with all samples in each category tested against a series of normal tissue samples (expression profiles of lung, liver, kidney, heart, adrenal, cerebrum, cerebellum, uterus, testes, stomach, spleen, bladder, skeletal muscle, prostate, and ovary, previously described in; Whiteford et al., [@B53]) in order to generate a *T*-statistic and *p* value, scoring each gene's expression level in each cancer type vs. normal expression levels. Genes in this auxiliary table were then sorted in order of descending differential expression.

Results
=======

Tumors analyzed
---------------

We restricted our current analysis to the 12 pediatric tumor types that had more than five samples available in the Pediatric Tumor Affymetrix Database: Pre-B Acute Lymphocytic Leukemia (Pre_B\_ALL), Embryonal Rhabdomyosarcoma (ERMS), Alveolar Rhabdomyosarcoma (ARMS), Soft-Tissue Sarcoma (STS) that is not classified as Rhabdomyosarcoma (Non-RMS_STS or simply STS), Desmoplastic Small Round Cell Tumor (DSRCT), Ewing's Sarcoma (EWS), Alveolar Soft Part Sarcoma (ASPS), Glioblastoma (GBM), Osteosarcoma (OS), Neuroblastoma-MYCN-amplified (NBL_MA, MYCNA-NBL), Neuroblastoma non-MYCN-amplified (NBL), and Hepatoblastoma (HBL). Some well-known tumors, like Wilm's tumor, could not yet be included; nevertheless, these 12 types represent the majority of all pediatric solid tumors, and also includes the most common hematologic malignancy of children.

Candidate antigens
------------------

We present here Pre_B\_ALL as an example to demonstrate how data mining searches were organized. A standard *t*-test was used to compare the average gene expression signal from tumor vs. the set of normal tissues analyzed in the database. The normal tissue data was used as an aggregate average expression score per each query. The algorithm was also set to report out a *p* value, while filtering for surface membrane expression to define the targets of interest. We initially calculated *t-*test values \> 10, and ordered the output to select for the highest *T* values. This process was repeated in a similar manner for each disease category. Table [1](#T1){ref-type="table"} shows the number of hits for each disease type in the database returned when this arbitrary *T* threshold of \>10 was selected. A wide range of hits was returned, with some diseases like ARMS having 62 hits score above 10, while DSRCT had 0. This does not mean DSRCT has no significant hits, as a *T*-statistic of 10 is a very high-value. Rather it illustrates that on a global level each malignancy has developed its own phenotypic "distance" from the normal cell surface landscape.

###### 

**Tumor-associated membrane proteins identified with a *T* value greater than 10**.

  **Disease**           **Sample size**, *n* =   **Hits**
  --------------------- ------------------------ ----------
  Pre-B ALL             9                        120
  ARMS                  12                       62
  ASPS                  7                        52
  Glioblastoma          7                        52
  NBL-MYCN-amplified    24                       44
  Non-RMS-STS           6                        38
  Osteosarcoma          17                       31
  Hepatoblastoma        7                        24
  Ewing's sarcoma       19                       22
  ERMS                  9                        16
  Neuroblastoma (NBL)   15                       4
  DSRCT                 8                        0

*The table lists the 12 disease categories analyzed and the number of individual gene expression profiles for each disease type currently featured in the Oncogenomics database. "Hits" refers to the number of tumor-associated membrane antigens reported whose *T* value is \> 10 in comparison to normal*.

A major challenge for our approach is that annotation of membrane-associated protein expression has not (or perhaps currently cannot) been validated for accuracy. On-line programs such as the highly sophisticated TMHMM package[^5^](#fn5){ref-type="fn"} can predict transmembrane structure, but cannot assign sub-cellular localization. The most extensive and accurate protein database groups (for example the Human Protein Reference Database/Pandey Lab[^6^](#fn6){ref-type="fn"}) are hand-annotating proteins and tracing them to the original literature in order to define sub-cellular localization. Therefore, we also had to utilize this approach and individually examine each membrane protein hit yielded by our algorithm by searching the available primary literature, primarily using Gene hosted by NCBI[^7^](#fn7){ref-type="fn"}, to determine if the "membrane" tag associated with a transcript's annotation truly denotes the extracellular plasma membrane. If an antigen is not expressed at the surface, that antigen will not be useful for immune targeting as we have described. We thus excluded proteins restricted to the mitochondria, nuclear membrane, Golgi, endoplasmic reticulum, sorting vesicles, and other intracellular membrane-bound bodies. Membrane proteins expressed both on the surface and another sub-cellular compartment were included. Table [2](#T2){ref-type="table"} lists the top 25 extracellular membrane proteins for each disease type after individual annotation/inspection.

###### 

**Top 25 pediatric cancer transcripts arranged by category**.

  ---------------------------------------------------------------------------------------------------------
  **CD antigens/immunology markers**
  CD19, B cell marker
  CD22, B cell marker
  CD25, IL2RA
  CD28
  CD30, TNFRSF8
  CD43, sialophorin
  CD49D, ITGA4 (VLA-4)
  CD53 (a tetraspanin)
  CD72, B cell marker
  CD73, NT5E
  CD79A, B cell marker
  CD79B, B cell marker
  CD85k, LILRB4, ILT3, leukocyte Ig-like R, subfamily B, member 4
  CD107a
  CD112, PVRL2 poliovirus R-related 2
  CD115, CSF1R, colony-stimulating factor 1 receptor
  CD146, MCAM, MUC18
  CD155, PVR, polio-virus receptor
  CD185, CXCR5
  CD204, MSR1, macrophage scavenger receptor 1
  CD271, NGFR
  CD276, B7-H3
  CD279, PDCD1 (PD1)
  CD280, MRC2, mannose R, C-type 2
  CD281, TLR1, toll-like receptor 1
  CD301 (CLEC10A)
  CD353, SLAMF8
  CD362, SDC2, syndecan 2
  CKLF, chemokine-like factor
  CLEC2D, C-type lectin domain family 2, member D (NK cells)
  FLT3LG
  GP1BB glycoprotein Ib, β polypeptide, CD42c
  HLA-G
  ICAM5, telencephalin
  IGHA1/IgA1
  IL1RAP, IL-1R accessory protein
  IL17RE, Interleukin-17 receptor E
  IL27RA, on EWS
  MILR1, mast cell Ig-like receptor 1
  MR1, MHC class 1-related
  PTCRA, pre-TCR α
  PODXL2, endoglycan, podocalyxin-like 2
  PTPRCAP, CD45-AP
  ULBP2, UL16 binding protein 2, NKG2D ligand 2, on OS
  XG, Xg blood group
  **Cell adhesion, cell junction**
  AJAP1 Adherens Junction Associated (SHREW-1, binds CD147)
  ASGR1, R2 (asialoglycoprotein receptor)
  MILR1, mast cell Ig-like 1, Allergin-1
  CADM1/IGSF4A, cell adhesion molecule 1
  CADM4/IGSF4C
  CDH15, cadherin 15, type 1, myotubule
  CDH23, cadherin-related 23
  CDHR5, MUCDHL
  CELSR3, cadherin, EGF LAG seven-pass G-type receptor 3
  CSPG4, chondroitin sulfate proteoglycan 4 (HMW-MAA, melanoma-associated)
  FAT4, FAT tumor suppressor homolog 4, protocadherin CDHF14
  GJA3, gap junction protein α 3 (connexin family)
  GJB2, gap junction protein β 2
  GPC2, glypican-2
  IGSF9, Ig superfamily, member 9
  LRFN4, leucine-rich repeat (LRR), and fibronectin type III domain containing 4
  LRRN6A/LINGO1, LRR, and Ig domain containing 1
  LRRC15, LRR containing 15
  LRRC8E, LRR containing 8E
  LRIG1, LRR, and Ig-like domains 1
  LGR4, LRR containing G-protein-coupled receptor 4 (R-spondin receptor)
  LYPD1, LY6/PLAUR domain containing 1
  MARVELD2, MARVEL domain containing 2
  MEGF10, multiple EGF-like domains 10, scavenger/phagocytic R
  MPZL1, myelin protein zero-like 1
  MTDH, metadherin
  PANX3, pannexin 3
  PCDHB10, protocadherin β 10
  PCDHB12, protocadherin β 12
  PCDHB13, protocadherin β 13
  PCDHB18, protocadherin β 18 pseudogene
  PCDHGA3, protocadherin γ subfam. A, 3
  PERP, TP53 apoptosis effector
  SGCB, sarcoglycan, β
  VEZT, vezatin, adherens junctions transmembrane protein
  **Enzymatic function**
  DAGLB, diacylgycerol lipase β
  SYT11, synaptogamin XI
  WFDC10A, WAP four-disulfide core domain 10A, peptidase inhibitor, extracellular
  **Growth factor R/development R**
  ACVR2A, Activin R2A
  ACVR2B, Activin R2B
  EPHB2, ephrin receptor B2 (RTK)
  EPHB3, ephrin receptor B3
  EPHB4, ephrin receptor B4
  EFNB1, ephrin-B1
  EPOR, erythropoietin receptor
  FGFR2, fibroblast growth factor receptor 2
  FGFR4
  GALR2, galanin receptor 2 (GPCR)
  GLG1, Golgi glycoprotein 1, Cfr-1, cysteine rich FGFR, ESL-1, E-selectin ligand-1
  GLP1R, glucagon-like peptide 1 R
  HBEGF, heparin-binding EGF-like growth factor (cleaved at membrane)
  IGF2R insulin-like growth factor-2 receptor
  MET, met proto-oncogene, HGFR, hepatocyte growth factor receptor
  UNC5C, unc-5 homolog C, a netrin R
  VASN, vasorin, TGF-β R on vascular smooth muscle cells
  DLL3, delta-like 3, a notch ligand
  FZD10/CD350, frizzled homolog 10 (GPCR, Wnt pathway)
  KREMEN2, kringle containing transmembrane protein 2 (DKK1 receptor)
  TMEM198, MGC99813, required for Wnt signal transduction
  NRG1, neuregulin 1
  TMEFF1, transmembrane protein w/EGF-like, and two follistatin-like domains 1
  **Neurotransmitter receptor**
  ADRA2C, adrenergic A2C
  CHRNA1, cholinergic R, nicotinic, α 1 (muscle)
  CHRNB4, cholinergic R, nicotinic, β 4
  CHRNA3, cholinergic R, nicotinic, α 3
  CHRNG, cholinergic R, nicotinic, γ
  DRD4, dopamine R D4, G-protein linked
  GABRB3, GABA receptor, β3
  GRIN3A, glutamate R, ionotropic, *N*-methyl-[d]{.smallcaps}-aspartate 3A
  GRIN2C glutamate R, ionotropic, *N*-methyl [d]{.smallcaps}-aspartate 2C
  GRIK4 glutamate R, ionotropic, kainate 4
  HTR7 5-hydroxytryptamine (serotonin) R 7
  SLC6A2, solute carrier family 6 (neurotransmitter, noradrenalin), member 2
  SLC6A11, SLC6 (neurotransmitter transporter, GABA), member 11
  SLC6A15, SLC (neutral amino acid transporter), member 15
  SLC29A4, SLC29 (nucleoside transporters), member 4 (reuptake of monoamines into presynaptic neurons)
  Ion channels, ion channel regulation
  APT8B2 (ATPase, cation transport, phospholipid translocation)
  NKAIN4 (C20orf58), Na+/K+ transporting ATPase interacting 4.
  CACNA1A,Ca^2+^ channel, voltage-dependent, P/Q type, α 1A subunit
  CACNA1B, Ca^2+^ channel, voltage-dependent, L type, α 1B subunit
  CACNA1I, Ca^2+^ channel, voltage-dependent, α 1I subunit
  CACNG8, Ca^2+^ channel, voltage-dependent, γ subunit 8
  CACNG4, Ca^2+^ channel, voltage-dependent, γ subunit 4
  CLCN7, chloride channel 7
  NKAIN1, Na^+^/K^+^ transporting ATPase interacting 1, FMA77C
  NKAIN4, Na^+^/K^+^ transporting ATPase interacting 4, C20orf58
  KCNEA4, K^+^ voltage-gated channel, Isk-related family, member 4
  KCNG2, K^+^ voltage-gated channel, subfamily G, member 2
  KCNN3, K^+^ intermediate/small conductance Ca^2+^-activated channel, subfamily N, member 3
  KCNQ2, K^+^ voltage-gated channel, KQT-like subfamily, member 2
  KCNU1, K^+^ channel, subfamily U, member 1
  P2RX3, purigenic receptor P2X, ligand-gated ion channel, 3
  PKD1L2, polycystic kidney disease 1-like 2
  PKD2L1, polycystic kidney disease 2-like 1
  SLC9A1, SLC9 (Na^+^/H^+^ exchanger), member 1
  SLC30A5, SLC30 (zinc transporter), member 5
  SLC39A7, SLC39 (zinc transporter), member 7
  SLC39A8, SLC39 (zinc transporter), member 8
  TRPM4, transient receptor, potential cation channel, subfamily M, member 4
  TRPV4, transient receptor, potential cation channel, subfamily V, member 4
  TMEM16J/ANO9, anoctamin 9, Ca^2+^-activated Cl- channel
  TMEM142B, ORAI2, ORAI Ca^2+^ release-activated Ca^2+^modulator 2
  **SLC, solute carrier family members**
  SLC6A15, SLC6 (neutral amino acid transporter), member 15
  SLC5A8, SLC5 (iodide transporter), member 8
  SLC7A1, SLC7 (cationic amino acid transporter, y+ system), member 1
  SLC7A6, SLC7 (amino acid transporter light chain, y + L system), member 6
  SLC10A3, SLC10 (sodium/bile cotransporter family), member 3
  SLC10A4, SLC10 (sodium/bile acid cotransporter family), member 4
  SLC13A5, SLC13 (sodium-dependent citrate transporter), member 5
  SLC16A8, SLC16, member 8 (monocarboxylic acid transporter 3)
  SLC19A1, FOLT, SLC19 (folate transporter), member 1
  SLC35E2, SLC35, member E2
  SLC38A6, SLC38, member 6
  SLC38A9, SLC38, member 9 (putative sodium-coupled neutral amino acid transporter 9)
  SLC43A3, EEG1 (embryonic epithelial gene-1), SLC43, member 3
  **G-protein, G-protein coupled, or associated receptor**
  ADORA2B, Adenosine R
  BAI1 (brain angiogenesis inhibitor 1)
  EDG6, S1PR4, sphingosine-1-phosphate R4
  GPR1, G-coupled protein receptor 1
  GPR26
  GPR34
  GPR44, PTGDR2 prostaglandin D2 receptor 2
  GPR56
  GPR68 (OGR-1, ovarian cancer G-protein-coupled receptor 1)
  GPR175, TPRA1 transmembrane protein, adipocyte associated 1
  LGR4, LRR containing G-protein-coupled receptor 4
  MMD, monocyte macrophage differentiation-associated (has 7 transmembrane domains, not proven as a GPCR)
  NTSR2, neurotensin receptor 2
  OPN3, opsin 3
  OR2L2, olfactory R, family 2, subfamily L, member 2
  OSTM1, osteopetrosis associated transmembrane protein 1
  P2RY8, purinogenic R P2Y, G-coupled, 8
  P2RY11, purinogenic R P2Y, G-coupled, 11
  PTGE3, prostaglandin E R 3 (subtype EP3)
  SSTR5, somatostatin R 5
  TBXA2R, thromboxane A2 receptor
  **Migration/metastasis/motility**
  ADAM22
  CST11, cystatin 11 (epididymal specific)
  MMP14, matrix metallopeptidase 14
  LPPR1, RP11-35N6.1, lipid phosphate phosphatase-related protein type 1
  LPPR3, PRG2 (plasticity related gene 2), LPPR type 3
  LPPR5, PAP2D, PRG5, LPPR type 5
  SEMA6B, semaphorin 6B
  **Tetraspanin**
  ALS2CR4 (amyotrophic lateral sclerosis 2 \[juvenile\])
  LEPROTL1, leptin R overlapping transcript-like 1
  MS4A4A, membrane-spanning, 4-domains, subfamily A, member 4A, CD20L1
  MS4A6A, membrane-spanning 4-domains, subfamily A, member 6A, CD20L3
  ROM1, retinal outer segment membrane protein 1
  TM4SF5, transmembrane 4 L six family member 5
  VANGL1, vang-like 1 (van gogh, Drosophila)
  VANGL2, vang-like 2
  **Uncharacterized**
  C18orf1 (contains a LDLRA domain)
  GSGL1, germ cell specific gene 1-like
  ITM2A, integral membrane protein 2A
  KIAA1715, LNP
  LDLRAD3 (provisional), LDL receptor class A domain containing 3
  ODZ3,odz Oz/ten-m homolog 3
  SLC7A5P1 (LAT1-3TM) SLC7 (aminoacid transporter light chain, L system), member 5, psuedogene-1
  STEAP1, six transmembrane epithelial antigen of the prostate 1
  ---------------------------------------------------------------------------------------------------------

*The pediatric top 25. The membrane-bound proteins with the highest *T* value with respect to normal tissue expression are listed by disease type. ALL, Pre-B, Acute Lymphocytic Leukemia; ASPS, Alveolar Soft Part Sarcoma; DSRCT, Desmoplastic Small Round Cell Tumor; ERMS, Embryonal Rhabdomyosarcoma; ARMS, Alveolar Rhabdomyosarcoma; Non-RMS_STS or simply STS, Soft-Tissue Sarcoma that is not classified as Rhabdomyosarcoma; EWS, Ewing's Sarcoma; GBM, Glioblastoma; OS, Osteosarcoma; NBL_MA, MYCNA-NBL, Neuroblastoma-MYCN-amplified; NBL, Neuroblastoma non-MYCN-amplified; HBL, Hepatoblastoma. This list was individually annotated to include only those transcripts whose proteins could be targeted from their extracellular aspect*.

To compare global differences in the immune landscape for the 25 antigens most different from normal for each tumor type, we plotted the *T* value range of those 25 hits for each tumor type, Figure [1](#F1){ref-type="fig"}. When comparing the expression of a particular transcript in a tumor type versus normal tissue, we used a *T*-statistic and report the associated *p* value for that particular transcript (both with respect to difference from normal tissue). In looking at the top 25 hits for each tumor type, the lowest set of *T* values (that is membrane proteins that were least distinct from normal), were DSRCT and NBL. *T* values ranged from 9.3 to 6.9 for DSRCT and from 12.6 to 5.8 for NBL. The highest *T* values (tissues scoring the most different from normal) were seen for ASPS, Pre-B ALL, STS, and ARMS, which scored from 25.5 to 12.5, 19.8 to 11.0, 15.0 to 9.8, and 27.7 to 10.0, respectively. When *p* values were evaluated an essentially inverse pattern was seen; that is, high scoring *T* values had smaller (more significant) *p* values (not shown). These values demonstrate very good separation from normal and represent a set of targets that are important to further evaluate in each of these tumor types. As to the true immunogenicity of these tumor types, further studies are required to determine whether these differences can be accounted for by different strategies of immune escape or immune editing (Schreiber et al., [@B47]).

![***T*-Statistic overview of the top 25 tumor-specific transcripts**. For each disease category (listed on the *x*-axis), the range of *T*-statistic values for the 25 membrane proteins most different from normal tissue, along with their average and quartiles, is represented as a box and whisker plot.](fonc-02-00194-g001){#F1}

To better understand the antigens we have identified, we ordered the transcripts according to functional groups (Table [3](#T3){ref-type="table"}). The first group consists of known CD antigens or immune marker proteins. The possession of a CD designation ensures that an antibody has been created to that transcript. The only known CD antigen we did not list in this section was CD222 (glucagon-like peptide 1 R), which was placed in the growth factor receptor category. In the CD antigen group, 12 out of 47 (appx. 25%) are expressed in pre-B ALL. This is representative of the tissue of origin, as CD antigens are often of immune cell origin. Nevertheless, many CD antigens are also expressed on other pediatric tumors.

###### 

**Pediatric tumor antigens arranged by functional category**.

                    Affy ID         Gene symbol     *T* value   *P* value   Gene name
  ----------------- --------------- --------------- ----------- ----------- -----------------------------------------------------------------------------------
  **ALL (PRE-B)**                                                           
  1                 206398_s\_at    CD19            19.85       1.56E−15    CD19 molecule
  2                 205049_s\_at    CD79A           17.90       1.33E−14    CD79a, immunoglobulin-associated alpha
  3                 205885_s\_at    CD49D           16.64       6.01E−14    Integrin, alpha 4 (VLA-4)
  4                 205297_s\_at    CD79B           16.18       1.06E−13    CD79b, immunoglobulin-associated beta
  5                 1568964_x\_at   CD43            15.80       1.71E−13    Sialophorin (leukosialin)
  6                 222935_x\_at    SLC39A8         14.78       6.59E−13    Solute carrier family 39 (zinc transporter)
  7                 209776_s\_at    SLC19A1         13.84       2.47E−12    Solute carrier family 19 (folate transporter)
  8                 204960_at       CD45-AP         13.59       3.50E−12    PTPRCAP, CD45-associated protein
  9                 229686_at       P2RY8           13.57       3.61E−12    Purinergic R P2Y, G-protein coupled, 8 (fused w/CRLF2 in pre-B ALL (Mullighan'09)
  10                214546_s\_a     P2RY11          13.26       5.73E−12    Purinergic R P2Y, G-protein coupled, 11
  11                236186_x\_at    IL17RE          13.22       6.03E−12    Interleukin 17 receptor E
  12                210176_at       CD281           12.70       1.32E−11    Toll-like receptor 1
  13                206437_at       SIPR4           12.64       1.46E−11    Sphingosine-1-phosphate R 4, EDG6
  14                215925_s\_at    CD72            12.58       1.60E−11    CD72 molecule
  15                212250_at       MTDH            12.47       1.89E−11    Metadherin
  16                211042_x\_at    CD146/MCAM      12.38       2.18E−11    Melanoma cell adhesion molecule (MUC18)
  17                220132_s\_at    CLEC2D          12.03       3.77E−11    C-type lectin domain family 2, member D
  18                217513_at       MILR1           11.66       6.94E−11    Mast cell immunoglobulin-like receptor 1
  19                208590_x\_at    GJA3            11.38       1.09E−10    Gap junction protein, alpha 3, 46kDa
  20                217422_s\_at    CD22            11.33       1.18E−10    CD22 molecule
  21                209574_s\_at    C18orf1         11.29       1.26E−10    Chromosome 18 open reading frame 1
  22                203578_s\_at    SLC7A6          11.09       1.78E−10    SLC7 (cationic a. a. transporter), member 6
  23                239422_at       GPC2            11.09       1.79E−10    Glypican 2 (cerebroglycan)
  24                208299_at       CACNA1I         11.07       1.85E−10    Ca channel, voltage-dep., alpha 1I subunit
  25                203416_at       CD53            11.05       1.91E−10    CD53 molecule
  **ASPS**                                                                  
  1                 209963_s\_at    EPOR            25.54       1.90E−20    Erythropoietin receptor
  2                 235197_s\_at    OSTM1           24.96       3.45E−20    Osteopetrosis assoc. transmembr. protein 1
  3                 227393_at       ANO9            22.55       4.75E−19    Anoctamin 9 (TMEM16J)
  4                 244444_at       PKD1L2          18.60       6.34E−17    Polycystic kidney disease 1-like 2
  5                 202827_s\_at    MMP14           18.42       8.12E−17    Matrix metallopeptidase 14
  6                 222379_at       KCNE4           15.65       4.62E−15    K voltage-gated channel, member 4
  7                 234985_at       LDLRAD3         15.45       6.23E−15    LDL receptor class A domain containing 3
  8                 206899_at       NTSR2           15.25       8.68E−15    Neurotensin receptor 2
  9                 219607_s\_at    MS4A4A/CD20L1   15.07       1.16E−14    Membrane-spanning 4-domains, A4
  10                230550_at       MS4A6A/CD20L3   14.78       1.83E−14    Membrane-spanning 4-domains, A6
  11                38069_at        CLCN7           14.49       2.96E−14    Chloride channel 7
  12                214830_at       SLC38A6         14.21       4.77E−14    Solute carrier family 38, member 6
  13                206582_s\_at    GPR56           14.14       5.32E−14    G protein-coupled receptor 56
  14                201393_s\_at    IGF2R/CD222     13.93       7.66E−14    Insulin-like growth factor 2 receptor
  15                206545_at       CD28            13.49       1.63E−13    CD28 molecule
  16                208552_at       GRIK4           13.48       1.65E−13    Glutamate receptor, ionotropic, kainate 4
  17                219764_at       FZD10/CD350     13.34       2.12E−13    FZD10/frizzled homolog 10
  18                223620_at       GPR34           13.03       3.69E−13    G protein-coupled receptor 34
  19                210514_x\_at    HLA-G           13.00       3.87E−13    HLA-G histocompatibility antigen, class I, G
  20                214770_at       MSR1/CD204      12.86       5.05E−13    Macrophage scavenger receptor 1
  21                206980_s\_at    FLT3LG          12.79       5.70E−13    Fms-related tyrosine kinase 3 ligand
  22                203104_at       CSF1R/CD115     12.76       6.06E−13    Colony stimulating factor 1 receptor
  23                207565_s\_at    MR1             12.58       8.32E−13    MHC, class I-related
  24                213728_at       CD107a          12.50       9.76E−13    LAMP1
  25                210692_s\_at    SLC43A3         12.48       1.01E−12    Solute carrier family 43, member 3 (EEG)
  **DRCT**                                                                  
  1                 212662_at       CD155           9.34        6.28E−09    Poliovirus receptor
  2                 211879_x\_at    PCDHGA3         9.13        9.24E−09    Protocadherin gamma subfamily A, 3
  3                 206083_at       BAI1            8.81        1.71E−08    Brain-specific angiogenesis inhibitor 1
  4                 219692_at       KREMEN2         7.80        1.24E−07    Kringle containing transmembrane protein 2
  5                 214546_s\_at    P2RY11          7.71        1.49E−07    Purinergic R P2Y, G-protein coupled, 11
  6                 215169_at       SLC35E2         7.66        1.63E−07    Solute carrier family 35, member E2
  7                 227281_at       SLC29A4         7.62        1.78E−07    SLC29 (nucleoside transporters), member 4
  8                 210651_s\_at    EPHB2           7.51        2.22E−07    EPH receptor B2
  9                 204600_at       EPHB3           7.43        2.64E−07    EPH receptor B3
  10                208215_x\_at    DRD4            7.39        2.85E−07    Dopamine receptor D4
  11                207634_at       CD279/PD1       7.38        2.91E−07    Programmed cell death 1
  12                220798_x\_at    LPPR3/PRG2      7.32        3.33E−07    Lipid phosphate phosphatase-related pr. 3
  13                239422_at       GPC2            7.18        4.49E−07    Glypican 2 (cerebroglycan)
  14                230668_at       NKAIN4          7.17        4.56E−07    Na++/K++ transporting ATPase interacting 4
  15                206906_at       ICAM5           6.97        6.92E−07    Intercellular adhesion molecule 5
  16                203149_at       CD112           6.82        9.71E−07    PVRL2, poliovirus receptor-related 2
  17                204736_s\_at    CSPG4           6.77        1.07E−06    Chondroitin sulfate proteoglycan 4
  18                222293_at       CADM4/IGSF4C    6.69        1.29E−06    IGSF4C, Ig superfamily member 4C
  19                206460_at       AJAP1           6.64        1.43E−06    Adherens junction assoc. prot. 1 (SHREW-1)
  20                232415_at       PCDHB13         6.60        1.54E−06    Protocadherin beta 13
  21                206341_at       CD25            6.57        1.66E−06    Interleukin 2 receptor, alpha
  22                236186_x\_at    IL17RE          6.45        2.16E−06    Interleukin 17 receptor E
  23                208590_x\_at    GJA3            6.40        2.42E−06    Gap junction protein, alpha 3, 46kDa
  24                214605_x\_at    GPR1            6.31        2.96E−06    G protein-coupled receptor 1
  25                216680_s\_at    EPHB4           6.29        3.10E−06    EPH receptor B4
  **EWS**                                                                   
  1                 1554062_at      XG              11.76       3.69E−13    Xg blood group
  2                 212250_at       MTDH            10.10       1.76E−11    Metadherin
  3                 218989_x\_at    SLC30A5         10.08       1.86E−11    SLC30 (zinc transporter), member 5
  4                 223675_s\_at    VEZT            10.05       2.01E−11    Vezatin
  5                 205542_at       STEAP1          9.96        2.49E−11    6 transmembr. epithelial ag of the prostate 1
  6                 219427_at       FAT4            9.94        2.62E−11    FAT tumor suppressor homolog 4
  7                 220798_x\_at    LPPR3/PRG2      9.78        3.90E−11    Lipid phosphate phosphatase-related prot. 3
  8                 239422_at       GPC2            9.51        7.60E−11    Glypican 2 (cerebroglycan)
  9                 235241_at       SLC38A9         9.51        7.64E−11    Solute carrier family 38, member 9
  10                227933_at       LRRN6A/LINGO1   9.41        9.91E−11    Leucine rich repeat neuronal 6A
  11                211042_x\_at    CD146/MCAM      9.27        1.38E−10    Melanoma cell adhesion molecule (MUC18)
  12                224392_s\_at    OPN3            9.15        1.89E−10    Opsin 3 (encephalopsin, panopsin)
  13                208299_at       CACNA1I         9.15        1.90E−10    Voltage-dependent, alpha 1I subunit
  14                219360_s\_at    TRPM4           9.11        2.11E−10    Transient R potential cation channel, M4
  15                208550_x\_at    KCNG2           8.71        5.86E−10    Voltage-gated channel, subfamily G2
  16                212909_at       LYPD1           8.50        1.03E−09    LY6/PLAUR domain containing 1
  17                205227_at       IL1RAP          8.50        1.04E−09    Interleukin 1 receptor accessory protein
  18                214730_s\_at    GLG1            8.44        1.22E−09    Golgi apparatus protein 1 (SEMA6C)
  19                202747_s\_at    ITM2A           8.41        1.30E−09    Integral membrane protein 2A
  20                209768_s\_at    CD42c           8.41        1.32E−09    GP1BB, glycoprotein Ib (platelet), beta
  21                222062_at       IL27RA          8.34        1.56E−09    Interleukin 27 receptor, alpha
  22                225717_at       KIAA1715        8.29        1.78E−09    KIAA1715 (Lnp, Lunapark)
  23                202711_at       EFNB1           8.28        1.86E−09    Ephrin-B1
  24                214830_at       SLC38A6         8.25        2.01E−09    Solute carrier family 38, member 6
  25                236186_x\_at    IL17RE          7.31        2.58E−08    Interleukin 17 receptor E
  **GBM**                                                                   
  1                 208590_x\_at    GJA3            11.85       1.69E−10    Gap junction protein, alpha 3, 46kDa
  2                 222935_x\_at    SLC39A8         11.16       4.88E−10    SLC39 (zinc transporter), member 8
  3                 217573_at       GRIN2C          11.02       6.04E−10    Glutamate R, ionotropic, NMDA 2C
  4                 212250_at       MTDH            10.77       8.95E−10    Metadherin
  5                 236186_x\_at    IL17RE          10.71       9.80E−10    Interleukin 17 receptor E
  6                 211226_at       GALR2           10.19       2.31E−09    Galanin receptor 2
  7                 205806_at       ROM1            9.72        5.12E−09    Retinal outer segment membrane protein 1
  8                 205891_at       ADORA2B         9.71        5.16E−09    Adenosine A2b receptor
  9                 232432_s\_at    SLC30A5         9.64        5.83E−09    SLC30 (zinc transporter), member 5
  10                208299_at       CACNA1I         9.50        7.47E−09    Ca channel, voltage-dependent, alpha 1I
  11                222596_s\_at    LGR4            9.47        7.87E−09    Leucine-rich repeat-containing GPCR4
  12                208550_x\_at    KCNG2           9.09        1.55E−08    K voltage-gated channel, subfamily G2
  13                1553995_a\_at   CD73            9.08        1.56E−08    5′-Nucleotidase, ecto
  14                207048_at       SLC6A11         8.99        1.84E−08    SLC6 (GABA transporter), member 11
  15                205120_s\_at    SGCB            8.79        2.66E−08    Sarcoglycan, beta
  16                235197_s\_at    OSTM1           8.77        2.74E−08    Osteopetrosis assoc. transmembrane prot. 1
  17                1556990_at      PERP            8.70        3.14E−08    PERP, TP53 apoptosis effector
  18                223451_s\_at    CKLF            8.68        3.25E−08    Chemokine-like factor
  19                211042_x\_at    CD146/MCAM      8.65        3.40E−08    Melanoma cell adhesion molecule (MUC18)
  20                240140_s\_at    LRIG1           8.61        3.69E−08    Leucine-rich repeats and Ig-like domains 1
  21                214546_s\_at    P2RY11          8.55        4.11E−08    Purinergic R P2Y, G-protein coupled, 11
  22                208229_at       FGFR2           8.28        6.85E−08    Fibroblast growth factor receptor 2
  23                202667_s\_at    SLC39A7         8.26        7.09E−08    SLC39 (zinc transporter), member 7
  24                209776_s\_at    SLC19A1         8.26        7.13E−08    SLC19 (folate transporter), member 1
  25                216464_x\_at    PTGDR2          8.15        8.72E−08    Prostaglandin D2 receptor 2/CD294
  **HBL**                                                                   
  1                 206242_at       TM4SF5          15.37       1.54E−12    Transmembrane 4  L six family member 5
  2                 212662_at       CD155           14.66       3.68E−12    Poliovirus receptor
  3                 235955_at       MARVELD2        12.90       3.75E−11    MARVEL domain containing 2
  4                 211576_s\_at    SLC19A1         12.26       9.25E−11    SLC19 (folate transporter), member 1
  5                 214546_s\_at    P2RY11          11.89       1.59E−10    Purinergic R P2Y, G-protein coupled, 11
  6                 206682_at       CD301           9.91        3.65E−09    C-type lectin domain family 10, member A
  7                 207634_at       CD279/PD1       9.61        6.20E−09    Programmed cell death 1
  8                 237273_at       KCNU1           9.55        6.82E−09    Potassium channel, subfamily U, member 1
  9                 206743_s\_at    ASGR1           9.53        7.04E−09    Asialoglycoprotein receptor 1
  10                223278_at       GJB2            9.27        1.11E−08    Gap junction protein, beta 2
  11                220028_at       ACVR2B          9.23        1.20E−08    Activin A receptor, type IIB
  12                209589_s\_at    EPHB2           9.10        1.50E−08    EPH receptor B2
  13                219796_s\_at    CDHR5           9.06        1.62E−08    Cadherin-related family member 5
  14                206130_s\_at    ASGR2           8.83        2.45E−08    Asialoglycoprotein receptor 2
  15                224392_s\_at    OPN3            8.74        2.92E−08    Opsin 3 (encephalopsin, panopsin)
  16                219386_s\_at    CD353           8.53        4.23E−08    SLAM family member 8 (CD353)
  17                227281_at       SLC29A4         8.44        5.04E−08    SLC29 (nucleoside transporters), member 4
  18                1553995_a\_at   CD73            8.41        5.35E−08    5′-Nucleotidase, ecto
  19                211249_at       GPR68           8.40        5.42E−08    G protein-coupled receptor 68
  20                228844_at       SLC13A5         8.33        6.18E−08    SLC13 (Na-dep. citrate transporter), 5
  21                213728_at       CD107a          8.12        9.28E−08    LAMP1
  22                211042_x\_at    CD146/MCAM      7.99        1.19E−07    Melanoma cell adhesion molecule (MUC18)
  23                207565_s\_at    MR1             7.86        1.53E−07    MHC, class I-related
  24                206361_at       PTGDR2          7.82        1.65E−07    Prostaglandin D2 receptor 2/CD294
  25                219732_at       LPPR1/PRG3      7.56        2.79E−07    Lipid phosphate phosphatase-related prot. 1
  **NB**                                                                    
  1                 239913_at       SLC10A4         12.60       4.66E−13    SLC10 (Na/bile acid cotransporter family), 4
  2                 210221_at       CHRNA3          9.39        3.75E−10    Cholinergic receptor, nicotinic, alpha 3
  3                 227281_at       SLC29A4         9.02        8.84E−10    SLC29 (nucleoside transporters), member 4
  4                 205122_at       TMEFF1          8.21        6.22E−09    TMEFF1
  5                 207516_at       CHRNB4          8.14        7.39E−09    Cholinergic receptor, nicotinic, beta 4
  6                 203414_at       MMD             7.75        1.93E−08    Monocyte to macrophage different.-assoc.
  7                 212290_at       SLC7A1          7.32        5.77E−08    SLC7 (cationic amino acid transporter), 1
  8                 218811_at       ORAI2           7.14        9.11E−08    ORAI Ca-release-activated Ca-modulator 2
  9                 221585_at       CACNG4          7.07        1.09E−07    Ca-channel, voltage-dep., gamma subunit 4
  10                239422_at       GPC2            7.01        1.26E−07    Glypican 2 (cerebroglycan)
  11                209198_s\_at    SYT11           6.95        1.46E−07    Synaptotagmin XI
  12                206343_s\_at    NRG1            6.92        1.62E−07    Neuregulin 1
  13                226029_at       VANGL2          6.65        3.26E−07    Vang-like 2 (van gogh, Drosophila)
  14                219491_at       LRFN4           6.63        3.42E−07    Leucine rich repeat and fn type III domain,4
  15                210353_s\_at    SLC6A2          6.57        3.97E−07    SLC6 (noradrenalin transporter), member 2
  16                219523_s\_at    ODZ3            6.49        4.96E−07    Odz, odd Oz/ten-m homolog 3 (Drosophila)
  17                1553956_at      TMEM237         6.42        5.96E−07    ALS2CR4, amyotrophic lateral sclerosis 2CR4
  18                1552914_a\_at   CD276           6.39        6.46E−07    CD276 molecule
  19                220798_x\_at    LPPR3/PRG2      6.31        7.97E−07    Lipid phosphate phosphatase-related pr. 3
  20                219152_at       PODXL2          6.18        1.14E−06    Podocalyxin-like 2
  21                40020_at        CELSR3          6.12        1.34E−06    Cadherin, EGF LAG seven-pass G-type R 3
  22                206189_at       UNC5C           6.12        1.34E−06    Unc-5 homolog C (netrin receptor)
  23                223854_at       PCDHB10         6.04        1.64E−06    Protocadherin beta 10
  24                208118_x\_a     SLC7A5P2        5.98        1.95E−06    SLC 7, member 5 pseudogene 2/IMAA
  25                225832_s\_at    DAGLBETA        5.86        2.65E−06    Diacylglycerol lipase beta
  **NBL-MYCNA**                                                             
  1                 239913_at       SLC10A4         14.03       2.18E−16    SLC10 (Na/bile acid cotransporter family), 4
  2                 205122_at       TMEFF1          13.74       4.15E−16    TMEFF1
  3                 219152_at       PODXL2          13.46       7.85E−16    Podocalyxin-like 2
  4                 210221_at       CHRNA3          13.12       1.74E−15    Cholinergic receptor, nicotinic, alpha 3
  5                 239422_at       GPC2            12.66       5.07E−15    Glypican 2 (cerebroglycan)
  6                 220798_x\_at    LPPR3/PRG2      12.58       6.16E−15    Lipid phosphate phosphatase-related pr. 3
  7                 211042_x\_at    CD146/MCAM      12.11       1.93E−14    Melanoma cell adhesion molecule (MUC18)
  8                 209776_s\_at    SLC19A1         11.23       1.77E−13    SLC19 (folate transporter), member 1
  9                 210508_s\_at    KCNQ2           11.11       2.43E−13    K voltage-gated channel, KQT-like, 2
  10                203414_at       MMD             10.91       4.09E−13    Monocyte to macrophage different.-assoc.
  11                219537_x\_at    DLL3            10.43       1.45E−12    Delta-like 3
  12                219438_at       NKAIN1          10.41       1.53E−12    Na + +/K + + transporting ATPase interacting 1
  13                227281_at       SLC29A4         10.40       1.55E−12    SLC29 (nucleoside transporters), member 4
  14                227690_at       GABRB3          10.35       1.80E−12    GABA, A receptor, beta 3
  15                226029_at       VANGL2          10.09       3.62E−12    Vang-like 2 (van gogh, Drosophila)
  16                242782_x\_at    TMEM198         9.89        6.20E−12    Transmembrane protein 198
  17                229276_at       IGSF9           9.39        2.46E−11    Immunoglobulin superfamily, member 9
  18                1553956_at      TMEM237         9.25        3.69E−11    ALS2CR4, amyotrophic lateral sclerosis 2CR4
  19                202594_at       LEPROTL1        9.13        5.15E−11    Leptin receptor overlapping transcript-like 1
  20                212290_at       SLC7A1          9.07        6.08E−11    SLC7 (cationic a.a. transporter),1/LAT1-3TM
  21                231397_at       LPPR5/PRG5      9.03        6.90E−11    PAP2D (phosphatidic acid phosphatase, 2)
  22                232263_at       SLC6A15         8.98        7.98E−11    SLC6, member 15
  23                1552914_a\_at   CD276           8.94        8.90E−11    CD276 molecule (B7-H3)
  24                219491_at       LRFN4           8.91        9.76E−11    LRFN4
  25                207162_s\_at    CACNA1B         8.86        1.12E−10    Ca channel, voltage-dep., L type, alpha 1B
  **OS**                                                                    
  1                 202667_s\_at    SLC39A7         12.57       1.75E−13    SLC39 (zinc transporter), member 7
  2                 240955_at       PANX3           11.06       4.14E−12    Pannexin 3
  3                 210087_s\_at    MPZL1           10.96       5.22E−12    Myelin protein zero-like 1
  4                 212250_at       MTDH            10.92       5.69E−12    Metadherin
  5                 238542_at       ULBP2           10.11       3.58E−11    UL16 binding protein 2 (NKG2D)
  6                 218989_x\_at    SLC30A5         9.93        5.34E−11    SLC30 (zinc transporter), member 5
  7                 206328_at       CDH15           9.78        7.67E−11    Cadherin 15, M-cadherin (myotubule)
  8                 209280_at       CD280           9.45        1.70E−10    MRC2, mannose receptor, C type 2
  9                 219330_at       VANGL1          9.18        3.21E−10    Vang-like 1 (van gogh, Drosophila)
  10                202828_s\_at    MMP14           9.07        4.21E−10    Matrix metallopeptidase 14
  11                239433_at       LRRC8E          8.82        7.90E−01    Leucine rich repeat containing, 8E
  12                218855_at       GPR175          8.67        1.13E−09    TPRA1
  13                211042_x\_at    CD146/MCAM      8.57        1.47E−09    Melanoma cell adhesion molecule (MUC18)
  14                225867_at       VASN            8.44        2.04E−09    Vasorin
  15                204928_s\_at    SLC10A3         8.34        2.60E−09    SLC10 (Na/bile acid cotransporter fam.), 3
  16                206399_x\_at    CACNA1A         8.20        3.71E−09    Ca channel, voltage-dep. P/Q type, alpha 1A
  17                203578_s\_at    SLC7A6          8.00        6.31E−09    SPC7 (cationic amino acid transporter), 6
  18                212662_at       CD155           7.98        6.53E−09    Poliovirus receptor
  19                208299_at       CACNA1I         7.88        8.61E−09    Ca channel, voltage-dep., alpha 1I subunit
  20                209030_s\_at    CADM1/IGSF4A    7.88        8.66E−09    Immunoglobulin superfamily, member 4
  21                213909_at       LRRC15          7.72        1.29E−08    Leucine rich repeat containing 15
  22                205120_s\_at    SGCB            7.54        2.09E−08    Sarcoglycan, beta
  23                220455_at       SLC16A8         7.48        2.43E−08    SLC16, member 8
  24                211837_s\_at    PTCRA           7.43        2.77E−08    Pre T-cell antigen receptor alpha
  25                239422_at       GPC2            7.40        3.00E−08    Glypican 2 (cerebroglycan)
  **ARMS**                                                                  
  1                 211042_x\_at    CD146/MCAM      27.68       2.82E−20    Melanoma cell adhesion molecule (MUC18)
  2                 206633_at       CHRNA1          24.21       7.16E−19    Cholinergic R, nicotinic, alpha 1 (muscle)
  3                 211237_s\_at    FGFR4           19.67       1.00E−16    Fibroblast growth factor receptor 4
  4                 236517_at       MEGF10          19.19       1.78E−16    Multiple EGF-like-domains 10
  5                 205327_s\_at    ACVR2A          14.78       7.27E−14    Activin A receptor, type IIA
  6                 205903_s\_at    KCNN3           14.00       2.46E−13    K intermediate/small conductance, CNN3
  7                 206328_at       CDH15           13.85       3.14E−13    Cadherin 15, M-cadherin (myotubule)
  8                 224182_x\_at    SEMA6B          12.15       5.46E−12    Semaphorin 6B
  9                 239422_at       GPC2            11.89       8.69E−12    Glypican 2 (cerebroglycan)
  10                205858_at       CD271/NGFR      11.43       2.03E−11    NGFR, nerve growth factor receptor
  11                208299_at       CACNA1I         11.30       2.60E−11    Ca channel, voltage-dep., alpha 1I subunit
  12                203510_at       MET             11.07       3.97E−11    Met proto-oncogene
  13                221408_x\_at    PCDHB12         10.99       4.65E−11    Protocadherin beta 12
  14                219692_at       KREMEN2         10.85       6.01E−11    Kringle containing transmembrane protein 2
  15                221355_at       CHRNG           10.80       6.64E−11    Cholinergic receptor, nicotinic, gamma
  16                212157_at       CD362/SDC2      10.59       1.00E−10    Syndecan 2
  17                211693_at       IGHA1           10.43       1.36E−10    Immunoglobulin heavy constant alpha 1
  18                212290_at       SLC7A1          10.41       1.43E−10    SLC7 (cationic a.a. transp., y++ system), 1
  19                211837_s\_at    PTCRA           10.32       1.70E−10    Pre T-cell antigen receptor alpha
  20                207555_s\_at    TBXA2R          10.29       1.80E−10    Thromboxane A2 receptor
  21                230668_at       NKAIN4          10.28       1.83E−10    Na++/K++ transporting ATPase interacting 4
  22                222596_s\_at    LGR4            10.01       3.11E−10    Leucine-rich repeat-containing GPCR4
  23                206128_at       ADRA2C          9.99        3.27E−10    Adrenergic, alpha-2C-, receptor
  24                209776_s\_at    SLC19A1         9.98        3.31E−10    SLC19 (folate transporter), member 1
  25                221450_x\_at    PCDHB13         9.96        3.45E−10    Protocadherin beta 13
  **ERMS**                                                                  
  1                 211042_x\_at    CD146/MCAM      20.87       5.46E−16    Melanoma cell adhesion molecule (MUC18)
  2                 206633_at       CHRNA1          12.63       1.47E−11    Cholinergic R, nicotinic, alpha 1 (muscle)
  3                 239422_at       GPC2            11.62       7.31E−11    Glypican 2 (cerebroglycan)
  4                 208299_at       CACNA1I         11.07       1.83E−10    Ca channel, voltage-dependent, alpha 1I
  5                 206328_at       CDH15           11.00       2.06E−10    Cadherin 15, M-cadherin (myotubule)
  6                 224182_x\_at    SEMA6B          11.00       2.07E−10    Semaphorin 6B
  7                 236701_at       GSG1L           10.62       4.00E−10    GSG1-like (has a PMP22 claudin domain)
  8                 236186_x\_at    IL17RE          10.28       7.27E−10    Interleukin 17 receptor E
  9                 222596_s\_at    LGR4            10.06       1.08E−09    Leucine-rich repeat-containing GPCR4
  10                214555_at       SSTR5           9.88        1.51E−09    Somatostatin receptor 5
  11                207048_at       SLC6A11         9.69        2.14E−09    SLC6 (GABA transporter), member 11
  12                236517_at       MEGF10          9.58        2.64E−09    Multiple EGF-like-domains 10
  13                205327_s\_at    ACVR2A          9.52        2.92E−09    Activin A receptor, type IIA
  14                216680_s\_at    EPHB4           9.52        2.95E−09    EPH (ephrin) receptor B4
  15                237503_at       SLC5A8          9.45        3.32E−09    Solute carrier family 5, member 8
  16                209769_s\_at    CD42c           9.40        3.71E−09    GP1BB, glycoprotein Ib, beta polypeptide
  17                211693_at       IGHA1           9.10        6.57E−09    Immunoglobulin heavy constant alpha 1
  18                211837_s\_at    PTCRA           9.09        6.67E−09    Pre T-cell antigen receptor alpha
  19                209280_at       CD280           9.08        6.75E−09    MRC2, mannose receptor, C type 2
  20                209776_s\_at    SLC19A1         8.71        1.40E−08    SLC19 (folate transporter), member 1
  21                222935_x\_at    SLC39A8         8.65        1.59E−08    SLC39 (zinc transporter), member 8
  22                207927_at       HTR7            8.59        1.76E−08    5-Hydroxytryptamine (serotonin) receptor 7
  23                214546_s\_at    P2RY11          8.19        3.96E−08    Purinergic RP2Y, G-protein coupled, 11
  24                207555_s\_at    TBXA2R          8.12        4.56E−08    Thromboxane A2 receptor
  25                234724_x\_at    PCDHB18         7.99        6.03E−08    Protocadherin beta 18 pseudogene
  **Non_RMS_STS**                                                           
  1                 244857_at       HBEGF           15.03       5.30E−12    Heparin-binding EGF-like growth factor
  2                 207555_s\_at    TBXA2R          14.55       9.40E−12    Thromboxane A2 receptor
  3                 208338_at       P2RX3           14.40       1.13E−11    Purinergic R P2X, ligand-gated ion channel, 3
  4                 210152_at       CD85k/LILRB4    13.51       3.41E−11    Leukocyte Ig-like receptor, subfamily B4
  5                 211693_at       IGHA1           12.80       8.60E−11    Immunoglobulin heavy constant alpha 1
  6                 206616_s\_a     ADAM22          12.76       9.07E−11    ADAM metallopeptidase domain 22
  7                 211909_x\_at    PTGER3          12.25       1.84E−10    Prostaglandin E receptor 3 (subtype EP3)
  8                 214546_s\_at    P2RY11          12.01       2.57E−10    Purinergic R P2Y, G-protein coupled, 11
  9                 233171_at       GRIN3A          11.77       3.57E−10    Glutamate receptor, ionotropic, NMDA 3A
  10                219516_at       TRPV4           11.57       4.76E−10    Transient R potential cation channel, V4
  11                234756_at       CACNG8          11.49       5.41E−10    Ca channel, voltage-dep., gamma subunit 8
  21                1554728_at      SLC9A1          11.35       6.55E−10    SLC9 (Na/H exchanger), member 1
  13                206729_at       CD30            11.13       9.07E−10    (TNFRSF8, Ki-1)
  14                216734_s\_at    CD185           11.03       1.07E−09    CXCR5
  15                207927_at       HTR7            11.02       1.07E−09    5-Hydroxytryptamine (serotonin) receptor 7
  16                208401_s\_at    GLP1R           10.99       1.13E−09    Glucagon-like peptide 1 receptor
  17                233968_at       CST11           10.96       1.17E−09    Cystatin 11
  18                232846_s\_at    CDH23           10.88       1.34E−09    Cadherin-like 23
  19                233913_at       WFDC10A         10.71       1.73E−09    WAP four-disulfide core domain 10A
  20                207048_at       SLC6A11         10.65       1.89E−09    SLC6 (GABA transporter), member 11
  21                1567238_at      OR2L2           10.37       2.92E−09    Olfactory R, family 2, subfamily L, member 2
  22                221061_at       PKD2L1          10.33       3.10E−09    Polycystic kidney disease 2-like 1
  23                244617_at       GPR26           10.18       3.93E−09    G protein-coupled receptor 26
  24                216873_s\_at    ATP8B2          10.02       5.14E−09    ATPase, Class I, type 8B, member 2
  25                211399_at       FGFR2           9.83        6.88E−09    Fibroblast growth factor receptor 2

*Antigens identified in Table [2](#T2){ref-type="table"} were grouped according to functional activity (CD antigens/markers, cell adhesion or cell junction, enzymatic function, growth factor or developmental factor receptor, neurotransmitter receptor, ion channel protein or ion channel regulator, SLC, solute carrier family member, G-protein or G-protein associated, migration or metastasis or cell motility function, tetraspanins, or uncharacterized) in order to give an overview of target types*.

Antigens in the "Cell Adhesion, Cell Junction" group include well-known adhesion family receptor members, like cadherins, cell-to-cell junction associated proteins, and other scavenger or immunoglobulin-related proteins. One would expect that the proteins in this family also would readily have antibodies created to them, and are likely to receive CD designations in the future. This is also likely to be true for the "Growth Factor Receptor/Development Receptor" grouping. These hits also provide ready targets such as the FGFR2, FGFR4, known oncogenes like MET, and the activin and ephrin receptors, that are likely to be linked to the oncogenic activation of the cancer tissues in which they are expressed. The final groups of cell surface proteins that are likely to be targetable are the "Migration/Metastasis/Motility" and the "Enzymatic Function" group. In general these proteins exhibit their activity outside of the cell and mediate interaction of the cell with its surrounding matrix.

Comprising about half the proteins on the list are membrane-expressed proteins to which it cannot be assumed an antibody or CAR exists or that could be readily generated. These groups are the Neurotransmitter Receptors, Ion Channels, Solute Carrier Family, Tetraspanin, and G-protein groups. Although exceptions certainly exist, these membrane proteins interact with small molecules or ions and transport them across the cell membrane, or they co-ordinate other proteins within the membrane. In general they do not evidence a large extracellular component.

Another way to ascribe relative value to the "hits" we have identified is to determine how broadly they are expressed across the different pediatric cancer types. Figure [2](#F2){ref-type="fig"} demonstrates that 12 proteins are expressed in at least three distinct disease categories, and that another 12 transcripts are expressed in more than three disease types. From this view, the highest value targets are MCAM and GPC2, which are expressed in the Top 25 for eight different cancers. Similarly, small molecule transporters like SLC19A1 and neurotransmitter receptors like purogenic G-protein coupled (P2RY11) are prevalent across histologies. Whether the limited size of their extracellular domains will affect the ability to target these antigens with antibody derivatives or CARs is unknown, but their prevalence across disease types makes this an interesting question.

![**Frequency of hits across disease category**. Transcripts appearing in the pediatric Top 25 were often shared between disease types. All of the transcripts expressed in more than three **(A)**, or at least three **(B)**, cancer types are listed. The *x*-axis lists the individual gene, and the stacked boxes represent presence of that transcript in the Top 25 for that disease type.](fonc-02-00194-g002){#F2}

Target-specific observations
----------------------------

The ability of our algorithm to identify high-value targets is demonstrated by our results for Pre-B ALL, where a number of cell surface molecules currently being targeted in the clinic were identified as hits, Table [2](#T2){ref-type="table"}. One of the most important immunotherapeutic trials to date features CAR-modified T-cells specific for CD19, which is the top hit for B_ALL (Kochenderfer et al., [@B24]; Porter et al., [@B45]). Another Top 25 hit, CD22, is the target of an antibody-toxin conjugate experimental protocol that continues to show promise for children with ALL (Mussai et al., [@B38]). Another target, CD79 is also the subject of interest in therapy for B cell malignancy, as antibody-drug conjugates are being developed and tested (Polson et al., [@B44]). While our bioinformatic approach is validated by these results with ALL, the value of our approach is in the identification of antigens of interest for pediatric solid tumors for which substantial numbers of candidate antigens have not been previously identified.

The two most broadly expressed targets we identified for pediatric solid tumors are melanoma cell adhesion molecule (MCAM, CD146, MUC18), and glypican-2 (GPC2). MCAM and GPC2 are expressed in eight of the 12 tumor types analyzed, Figure [2](#F2){ref-type="fig"}. The other most commonly expressed adhesion molecule, metadherin (MTDH), is expressed in four of 12 tumor types. MCAM is involved in the pathogenesis of melanoma, breast carcinoma, and other cancers (Wu et al., [@B55]; Zeng et al., [@B59]). Both antibody-based and vaccine approaches targeting MCAM/MUC18 have been proposed (Melnikova and Bar-Eli, [@B33]; Leslie et al., [@B29]). GPC2 (also know as cerebroglycan) is normally expressed in the developing brain (Stipp et al., [@B48]). Molecules in the same family, Glypican-3 and Glypican-5, have been described in melanoma, neuroblastoma, and rhabdomyosarcoma (Saikali and Sinnett, [@B46]; Nakatsura et al., [@B39],[@B40]; Williamson et al., [@B54]). Our report here of the specific expression of Glypican-2 on pediatric tumors should now focus attention on this glypican as well. Metadherin (MTDH) is expressed on hepatocellular carcinoma, may play a role in epithelial-to-mesenchymal transition (Zhu et al., [@B60]), and plays a role in the metastatic spread of breast cancer to the lung (Brown and Ruoslahti, [@B4]). These three adhesion receptors are therefore top candidates to explore further as targets in pediatric tumors given their overexpression and the ability to create antibodies against cell surface adhesion receptors.

The largest family of cell surface proteins is the G-proteins (GPCR, approximately 800 members), followed by the solute carrier family (SLC, approximately 380 members; Almen et al., [@B1]; Hoglund et al., [@B18]). One of our top hits, SLC19A1 (expressed in ALL, HBL, MYCNA-NBL, GBM, ERMS, and ARMS), is a folate transporter. Unlike the GPI-linked α folate receptor (FOLR1), which is currently the target of antibody-based trials, SLC19A1 (FOLT) is a multi-pass membrane protein that looks very much like an ion channel (Konner et al., [@B25]). Each of the SLC proteins are regulated in expression, responsive to cellular stress or nutritional requirement, and could serve as suitable immune targets, but little is known about targeting them. The better known GPCR, ion channels, and neurotransmitter receptors we have described have in some cases had antibodies produced against them. In general, producing antibodies, and therefore scFv and CARs, against multi-membrane pass proteins with limited extracellular sequence is more difficult than for proteins with large extracellular domains.

The solid pediatric malignancies we analyzed also preferentially overexpress a number of receptors associated with the activin and ephrin receptor systems. Hits in the activin family include ACVR2A (ERMS, ARMS), ACVR2B (HBL); and in the ephrin family, EPHB2 (DRCT, HBL), EPHB3 (DRCT), EPHB4 (ERMS, DRCT), and EFNB1 (EWS). Activins are growth factors in the TGF-β family that bind dual chain receptors composed of ligand-binding and signaling subunits. The ACVR2 chains have the ability to signal as constitutive kinases and are thought to regulate muscle growth through binding of myostatin (Lee et al., [@B28]). The ACVR2A/2B expression patterns and their biological activity make them very high-value hits for pediatric oncology. Ephrins function in neuronal development and are divided in to A and B types, as are the receptors that bind to them. The ligand, ephrin-B1, is a transmembrane protein and the receptors we list as Top 25 hits, all in the receptor tyrosine kinase family, are also of the B type. Aberrant expression of these family members has been described in colon carcinoma (Herath et al., [@B16]). EPHB4 plays a role in vascular development and may participate in tumor metastatic spread (Heroult et al., [@B17]). Antibodies to EphB4 have been described to inhibit tumor growth (Krasnoperov et al., [@B26]). Both activin and ephrin receptors are promising for further investigation as cell surface targets in pediatric solid tumors.

Fibroblast growth factor receptors (FGFRs) are of great interest in pediatric oncology, and our bioinformatic hit for FGFR4 in ARMS confirms our previous genomic studies. There are 4 FGFRs that mediate cellular activation by the more than 20 known fibroblast growth factors (Olsen et al., [@B42]). Alterations or mutation of the FGFRs have been described in a number of cancer types, and they have been proposed as targets for both kinase inhibitor chemotherapy as well as immunotherapy (Wesche et al., [@B52]). Our group had previously identified FGFR4 as a target in rhabdomyosarcoma using gene expression array analysis and we have demonstrated FGFR4 activity in disease (Taylor et al., [@B49]). The closely related FGFR2 was also identified as a hit in STS and GBM. FGFR2 has been associated with a number of cancers making both of these FGFRs exciting findings for pediatric oncology (Bai et al., [@B2]).

Disease-specific observations
-----------------------------

The most intriguing hit for Non-Rhabdomyosarcoma STS is CD30 (TNFRSF8). CD30 is the current target of a number of immunotherapy trials, and our report suggests that these reagents should be evaluated for use in STS (Kasamon and Ambinder, [@B23]). In DSRCT we find expression of two very exciting hits, poliovirus receptor (PVR)/CD115 and PVR-related 2 (PVRL2)/CD112. Both these adhesion molecules have been described as NK-ligands and should serve as suitable immune targets (Pende et al., [@B43]). An equally exciting target on DSRCT is PDCD1 (PD1/CD279). The antigen is well-described as an anti-immune effector and efforts to block or target PD1 in cancer are actively underway (Flies et al., [@B11]).

The immune markers expressed EWS represent a unique group of targets. XG, is part of the Xg blood group antigen, the only other member of which is CD99, a well-known over-expressed protein in EWS, and expression of these antigens is closely linked (Johnson, [@B21]). Although transcripts are known to be found in non-erythroid tissues not much else is known for this target (Fouchet et al., [@B12]). Meynet et al. ([@B34]), have also recently described XG as a marker for EWS and demonstrate that its expression is associated with poor outcome. Three cytokine receptors are expressed on EWS: IL17RE, IL27RA, and IL1RAP. A recent mutational study demonstrated that IL27RA has transforming potential, although its expression on non-lymphoid malignancies has not previously been described (Lambert et al., [@B27]). IL1RAP, Interleukin-1 receptor accessory protein, can exist as a membrane or soluble form and is essential for IL-1 receptor activity. Expression of IL1RAP has been described in endometriosis and various leukemias, notably in leukemia stem cells, making IL1RAP a high-value target for EWS (Jaras et al., [@B20]; Guay et al., [@B15]).

Glioblastoma expresses the immune markers in CD73/NT5E (5′ nucleotidase, ecto), and CKLF. CD73 is present on cancer exosomes and has been shown to blunt immune responses (Clayton et al., [@B9]). CD73 is also a hit for HBL. CKLF, chemokine-like factor 1, binds CCR4 and can be either secreted or membrane-bound and contains a MARVEL transmembrane domain (Chowdhury et al., [@B8]). MARVELD2 is a transmembrane protein associated with tight junction that serves as a hit for HBL. The wide distribution of these targets requires more developmental work before considering using them as immune targets. GALR2, galanin receptor 2, is a growth factor receptor that also is an interesting GBM target. GALR2 has been proposed as a therapeutic target in head and neck carcinoma and is an active area of study (Kanazawa et al., [@B22]). GAL2R targeting should be explored in GBM as well.

Osteosarcoma expresses the intriguing hit UL16 binding protein 2 (ULBP2), which is a ligand for the NK cell activation marker NKGD2. To date, ULBP2 has been thought of as a means to alert to immune system due to p53 activation on target cells, and not as a mean of cancer immune escape (Textor et al., [@B50]). The matrix metalloproteinase MMP14 is known to participate in tumor metastasis and is the subject of intense research activity, making this a high-value target in OS and ASPS (Zarrabi et al., [@B58]). VASN, vasorin, is a transforming growth factor beta (TGF-β) trap, its biology is regulated by ADAM17, and it appears to play a role in epithelial to mesenchymal transition in other cancer types (Malapeira et al., [@B30]). Both of these two OS surface targets may play a role in disease progression.

In the analysis of MYCN-Amplified Neuroblastoma (NBL-MYCNA) our algorithm identified one of the most interesting current targets, CD276 (B7-H3). CD276 is the target of a number of immune directed therapies in NBL (Castriconi et al., [@B5]). The other targets identified for NML-MYCNA and for NB are all of great interest, but CD276 is likely to be a focus of future immune based strategies.

Hepatoblastoma overexpresses ASGR1 asialoglycoprotein receptor 1, and ASGR2. ASGR2 serves as a receptor for a series of glycoproteins including those on the surface of hepatitis virus (Yang et al., [@B57]). The only report of association with cancer is the reported increase in the rate of cell division of colorectal carcinoma cell lines when grown on ASGR1 coated surfaces, which makes both ASGRs intriguing hits (Fang et al., [@B10]). Another potential target for HBL is MR1, MHC class I-related, which is also expressed in ASPS. MR1 is an invariant class I MHC molecule known to interact with a subset of T lymphocytes with invariant or restricted TCRs (Gozalbo-Lopez et al., [@B14]). The expression of MR1 in cancer has not been reported, making this a novel finding. CD301 (CLEC10A, C-type lectin domain family 10, member A) has not been reported in cancer either, but like any adhesion receptor it has the potential to mediate metastasis. Another adhesion receptor hit is CD353, SLAMF8 \[signal lymphocyte activation molecule (SLAM), family member 8\]. SLAM proteins are in the CD2 family of lymphocyte activation proteins and may also contribute to the activation of cancer cells (Furukawa et al., [@B13]).

Alveolar soft part sarcoma
--------------------------

ASPS is a very distinct entity as evidenced by the unique set of antigens we report as top 25 hits, many of which are not shared with other tumors. EPOR, the erythropoietin receptor, was the highest-ranking hit for ASPS. The ETV6-RUNX1 fusion in ALL activates transcription of EPOR and it is likely to contribute a growth signal to leukemia, making this a potential target of interest (Torrano et al., [@B51]). Two CD antigens that were strong hits for ASPS are also growth factor receptors. Colony-stimulating factor 1/CD115 (CSF1R) modulates a number of myeloid differentiation steps and inhibitors have been designed for a number of disease states (Hume and Macdonald, [@B19]). CD222/ insulin-like growth factor-2 (IGF2R) has long been recognized as a cancer-expressed protein (Martin-Kleiner and Gall Troselj, [@B31]). Each of these receptors should be explored as targets in ASPS. Also intriguing is the expression of HLA-G. HLA-G is a class I MHC paralog, normally expressed on placental cells, and its expression has been described on malignant cells, perhaps shielding them from immunosurveillance (Yan, [@B56]). CD204/macrophage scavenger receptor 1 (MSR1) is another immune molecule expressed on ASPS. Expression of CD204 on tumor stromal macrophages has been associated with aggressiveness in lung cancer (Ohtaki et al., [@B41]). Thus ASPS provides a number of CD or CD-like antigens that can be targeted by means of immunotherapy.

Discussion
==========

How a cell surface antigen expressed on a tumor becomes a locus of tumor-protective immune activation, and how this response spares healthy tissue has yet to be fully defined. An antigen may be "revealed" by inhibiting immune checkpoints, or newly recognized as an antigenic target by vaccination (such as with PMSA; May et al., [@B32]). The key for both approaches is that a response has been induced that now sufficiently differentiates between cancer and normal host tissue. What "sufficient differentiation" is, remains a term in need of clarification. For example, some self-antigens, such as CD20, can readily be targeted, while others, such as HER2, are highly dependent on how they are targeted. The mature B cells compartment is apparently dispensable, as use of anti-CD20 antibody in lymphoma therapy has demonstrated. Once the B cell compartment is no longer targeted by the therapy, the B cell population is then replenished. HER2 (Neu, CD340, ErbB-2) has been effectively targeted in thousands of women with breast cancer using anti-HER2 antibody. However, administration of a T-cell population expressing a HER2-specific CAR resulted in treatment related mortality. In this special instance a large number of anti-HER-2-CAR engineered T-cells presumably bound to the low levels of HER2 present in the lung, and a massive cytokine storm ensued leading to death (Morgan et al., [@B36]). This event clearly shows that "how" a tumor antigen is targeted by the immune system may be as important as the expression level of that antigen on various tissues. It also illustrates that we have yet to create a universal definition of whether or not it is safe to target a tumor antigen expressed at very low levels on normal tissue. Targeting B cell malignancies has worked so well because the mature B cell compartment that expresses CD20 and CD19 is expendable (Biagi et al., [@B3]). A database that would begin to define what an "expendable" normal tissue is would be ideal. However, we have yet to even clearly formulate this question with regard to a specific bioinformatic search algorithm. For pediatric cancers, the issue is even more concerning, as certain growth factor receptors may be present on normal tissue that are crucial to development, and would not be part of the "normal" gene expression signature, if it was defined by specimens from adult tissues. Before proceeding with targeting any of the antigens we have identified in this report, we must both confirm expression on tumor and more importantly, confirm as best as we can the lack of expression on "non-expendable" tissues. In this report we identified the major pediatric tumor-associated antigens that are expressed on the plasma membrane, as defined by standard gene chip analysis, statistical analysis, and filtering of annotated attributes. The strength of gene expression profiling is its utility in differential analysis (comparisons of transcript expression in different samples or comparison of tumor versus normal tissue). One potential drawback is that gene chip technology may be skewed, in some instances, toward identification of 3′ transcripts, and thus tumor-specific splice variations or deletions may be missed. Nevertheless studies, including our own, have shown a significant correlation between mRNA and protein levels (Chen et al., [@B7]). The Affymetrix plus2 array used here attempts to capture multiple independent measurements for each transcript and therefore measures expression of the major transcript as well as other splice variants. However a better more precise but not yet perfect measurement of the expression levels of each transcript is afforded by next generation technologies, e.g., whole RNA sequencing (RNAseq). We are pursuing these measurements, but until complete RNASeq is available for the major pediatric tumor types, along with normal tissue, our approach remains current. Validation with antibody or ligand-based staining for receptors in tumor normal tissues will be needed to definitively credential each candidate transcript.

Ultimately, we plan to continue to refine our definition of which membrane proteins can be safely targeted by CAR or antibody-based therapies, as new analysis techniques emerge. We propose that given the breadth of the antigen list presented here, that a large-scale effort be made to systematically evaluate cell surface targets on pediatric tumors for their potential for immunotherapy. Specifically, antibodies or scFv binding fragments for these antigens need to be screened in a large-scale manner for reactivity to normal tissues. The small size of the overall market in pediatric oncology for these reagents makes it unlikely that industry will engage in this approach on its own. However, given the wealth of genomic and proteomic data being generated, academia can take advantage of these findings and translate them into reagents that can be tested in pre-clinical settings. The analysis framework we present here may also inspire a new look at common adult malignancies, and encourage the development of a new generation of broad-based approaches for identifying immunotherapy targets.
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